Literature DB >> 91468

N-Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis.

G P Stec, A J Atkinson, M J Nevin, J P Thenot, T I Ruo, T P Gibson, P Ivanovich, F del Greco.   

Abstract

NAPA pharmacokinetics were studied in 6 functionally anephric patients. Distribution and nonrenal elimination of this drug were found to be the same as in individuals with normal renal function but renal clearance was reduced, resulting in a mean elimination t 1/2 of 41.9 hr (6.2 hr in normal subjects). Renal clearance of NAPA correlated well with ClCr. Dialysis removed NAPA from both red blood cells and plasma and increased ClT approximately fourfold. Dialysis itself resulted in a 77% reduction in ClS that limited the total amount of NAPA removed by this procedure. This reduction in ClS was sustained for at least 3 hr after dialysis and attenuated rebound in plasma NAPA concentrations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 91468     DOI: 10.1002/cpt1979265618

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.

Authors:  R A Blum; R K Kohli; N J Harrison; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 2.  Pharmacokinetics and pharmacodynamics in critically ill patients.

Authors:  H J Mann; D W Fuhs; F B Cerra
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

Review 3.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

4.  Analysis of the contributions of permeability and flow of intercompartmental clearance.

Authors:  G P Stec; A J Atkinson
Journal:  J Pharmacokinet Biopharm       Date:  1981-04

Review 5.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of N-acetylprocainamide.

Authors:  S J Connolly; R E Kates
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

7.  Distribution characteristics of mitoxantrone in a patient undergoing hemodialysis.

Authors:  L Boros; T Cacek; R B Pine; A C Battaglia
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.

Authors:  P Ylitalo; R Ruosteenoja; O Leskinen; T Metsä-Ketelä
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Pharmacokinetic modeling and simulation of procainamide and N-acetylprocainamide in a patient receiving continuous renal replacement therapy: a novel approach to guide renal dose adjustments.

Authors:  Ahmed N Mohamed; Ahmed M Abdelhady; Dustin Spencer; Kevin M Sowinski; James E Tisdale; Brian R Overholser
Journal:  Am J Kidney Dis       Date:  2013-04-04       Impact factor: 8.860

Review 10.  Elucidation of the pathophysiology of intradialytic muscle cramps: pharmacokinetics applied to translational research.

Authors:  Arthur J Atkinson
Journal:  Transl Clin Pharmacol       Date:  2019-12-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.